📊 IRME Key Takeaways
Is IR-Med, Inc. (IRME) a Good Investment?
IR-Med is a distressed medical device company with severe structural insolvency, negative stockholders' equity of -$625K, and catastrophic revenue collapse of -115% YoY alongside -$1.5M net losses. The company is cash flow negative with operating cash burn of -$181K, critically low liquidity (0.12x current ratio), and minimal cash reserves ($63K) that cannot sustain operations or service $800K in liabilities.
IR-Med’s fundamentals are extremely weak: revenue is effectively nonexistent and deteriorating, while losses remain large relative to its tiny asset base and cash position. The balance sheet is distressed, with negative equity, very low liquidity, and ongoing cash burn that raises serious doubt about financial sustainability without external funding.
Why Buy IR-Med, Inc. Stock? IRME Key Strengths
- Minimal capital expenditure requirements suggest low ongoing infrastructure costs
- Some operational focus in medical device sector with regulatory barriers to entry
- Diluted EPS improved year over year, indicating some reduction in per-share loss pressure
- Long-term debt is relatively small in absolute terms
- Operating cash burn is smaller than net loss, suggesting some non-cash loss components
IRME Stock Risks: IR-Med, Inc. Investment Risks
- Negative stockholders' equity indicates technical insolvency with liabilities exceeding assets by $625K
- Revenue essentially eliminated (-115% YoY) with only -$3K revenue in latest period indicating operational collapse
- Severe liquidity crisis with current ratio of 0.12x and only $63K cash against $800K total liabilities
- Persistent net losses of -$1.5M with negative operating cash flow of -$181K unsustainable without external capital injection
- Zero insider trading activity in 90 days suggests management has abandoned ship
- Revenue base is effectively absent and declined further, indicating poor commercialization traction
- Negative stockholders’ equity and a 0.12x current ratio signal severe balance-sheet and liquidity stress
- Continued negative operating cash flow and free cash flow imply likely dependence on new capital raises
Key Metrics to Watch
- Cash balance trajectory and runway
- Ability to reverse revenue decline or achieve strategic acquisition/recapitalization
- Quarterly burn rate and path to liquidity event or bankruptcy filing
- Debt restructuring or equity raise announcements
- Sustained positive revenue generation and commercialization progress
- Cash runway, working capital improvement, and any reduction in negative equity
IR-Med, Inc. (IRME) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 6,100.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
IRME Profit Margin, ROE & Profitability Analysis
IRME vs Healthcare Sector: How IR-Med, Inc. Compares
How IR-Med, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IR-Med, Inc. Stock Overvalued? IRME Valuation Analysis 2026
Based on fundamental analysis, IR-Med, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IR-Med, Inc. Balance Sheet: IRME Debt, Cash & Liquidity
IRME Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: IR-Med, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.07 indicates the company is currently unprofitable.
IRME Revenue Growth, EPS Growth & YoY Performance
IR-Med, Inc. Dividends, Buybacks & Capital Allocation
IRME SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for IR-Med, Inc. (CIK: 0001839133)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRME
What is the AI rating for IRME?
IR-Med, Inc. (IRME) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRME's key strengths?
Claude: Minimal capital expenditure requirements suggest low ongoing infrastructure costs. Some operational focus in medical device sector with regulatory barriers to entry. ChatGPT: Diluted EPS improved year over year, indicating some reduction in per-share loss pressure. Long-term debt is relatively small in absolute terms.
What are the risks of investing in IRME?
Claude: Negative stockholders' equity indicates technical insolvency with liabilities exceeding assets by $625K. Revenue essentially eliminated (-115% YoY) with only -$3K revenue in latest period indicating operational collapse. ChatGPT: Revenue base is effectively absent and declined further, indicating poor commercialization traction. Negative stockholders’ equity and a 0.12x current ratio signal severe balance-sheet and liquidity stress.
What is IRME's revenue and growth?
IR-Med, Inc. reported revenue of $-3.0K.
Does IRME pay dividends?
IR-Med, Inc. does not currently pay dividends.
Where can I find IRME SEC filings?
Official SEC filings for IR-Med, Inc. (CIK: 0001839133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRME's EPS?
IR-Med, Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRME a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, IR-Med, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRME stock overvalued or undervalued?
Valuation metrics for IRME: ROE of N/A (sector avg: 15%), net margin of 49,133.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRME stock in 2026?
Our dual AI analysis gives IR-Med, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is IRME's free cash flow?
IR-Med, Inc.'s operating cash flow is $-181.0K, with capital expenditures of $2.0K. FCF margin is 6,100.0%.
How does IRME compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 49,133.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.12 (avg: 2).